Format

Send to

Choose Destination
See comment in PubMed Commons below
Front Oncol. 2014 Jul 23;4:190. doi: 10.3389/fonc.2014.00190. eCollection 2014.

Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer.

Author information

1
Ottawa Hospital Research Institute , Ottawa, ON , Canada.
2
Ottawa Hospital Research Institute , Ottawa, ON , Canada ; Ottawa Hospital Cancer Centre , Ottawa, ON , Canada ; Department of Medicine, University of Ottawa , Ottawa, ON , Canada.

Abstract

Our ability to detect and directly target the oncogenic alterations responsible for tumor proliferation has contributed significantly to the management of lung cancer in the last decade. The therapeutic efficacy of molecularly targeted therapy is, however, mainly limited to patients harboring certain genetic mutations and is generally short-lived. Herein, we review primary and secondary drug resistance using the most well-studied of the molecularly targeted agents, the tyrosine kinase inhibitors targeting the epidermal growth factor (EGF) receptor, and the anaplastic lymphoma kinase (ALK) rearrangement, the current limitations of targeted therapies and their consequences on the management of patients with lung cancer.

KEYWORDS:

EGFR; acquired resistance; inhibition; molecular biology; primary resistance

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Frontiers Media SA Icon for PubMed Central
    Loading ...
    Support Center